You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

2077 Results
Drug
Oct 2023
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Intent: Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Feb 2026
Guidelines and Advice
Apr 2019
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Feb 2026
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Feb 2026

Pages